Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma): lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Early / localised	1
Second line	1
Other settings	1

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Localised at other sites	Involved-site radiotherapy (the FoRT trial tested the dose in follicular and marginal zone lymphoma).	FoRTMarginal zone lymphoma		73

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Disseminated or relapsed	Rituximab alone or with chlorambucil or bendamustine; zanubrutinib or lenalidomide-rituximab later (AUGMENT; MAHOGANY).	RituximabChlorambucilBendamustineZanubrutinibLenalidomideAUGMENTA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom		91

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Gastric, H. pylori-positive	H. pylori eradication first, with endoscopic follow-up; radiotherapy if the lymphoma persists.	Marginal zone lymphoma		-

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.